Table 1.

miRNAs involved Parkinson’s disease

miRNAs	Source	Cohort composition	Methods	Regulation	Reference
miR-29c-3p
	PBMCs	19 PD	microarrays	↓	[45]
		13 HC
	serum	10 PD	TLDA/qRT-PCR	↓	[46]
		10 HC
		20 PD
		20 HC*
		65 PD
		65 HC**
	serum	138 PD	qRT-PCR	↓	[47]
		112 HC
	serum	75 PD	qRT-PCR	↓	[48]
		77 HC
	serum	51 PD	qRT-PCR	↑	[49]
		20 HC
miR-19b-3p
	PBMCs	19 PD	microarrays	↓	[45]
		13 HC
	CSF	57 PD	NGS	↑	[50]
		65 HC
	serum	10 PD	TLDA/qRT-PCR	↓	[46]
		10 HC,
		20 PD
		20 HC*
		65 PD
		65 HC**
	CSF exosome	47 PD	TLDA/qRT-PCR	↓	[51]
		27 CTRL
		78 PD
		35 CTRL
	Serum exosome	109 PD	qRT-PCR	↓	[52]
		40 HC
miR-29a-3p
	whole	8 PD	qRT-PCR	↓	[53]
	blood	8 HC
	serum	10 PD	TLDA/qRT-PCR	↓	[46]
		10 HC,
		20 PD
		20 HC*
		65 PD
		65 HC**
	PBMCs	38 PD	qRT-PCR	↑	[54]
		38 HC
	serum	78 PD	qRT-PCR	↓	[48]
		80 HC
miR-24-3p
	Serum	6 PD	TLDA/qRT-PCR	↑	[55]
		5 HC
		25 PD*
		25 HC
	CSF	28 PD	qRT-PCR	↓	[56]
		28 PD
	Serum	109 PD	qRT-PCR	↑	[52]
	exosome	40 HC
miR-335-5p
	PBMCs	19 PD	microarrays	↓	[45]
		13 HC
	Serum	16 PD	microarrays	↑	[57]
		8 HC	qRT-PCR
	Serum	20 PD	qRT-PCR	↓	[58]
		20 HC
		20 PD
		20 HC
miR-433-3p
	CSF	57 PD	NGS	↓	[50]
		65 HC
	Plasma	46 PD	qRT-PCR	↓	[59]
		49 HC
	Plasma	99 PD	qRT-PCR	↑	[60]
		100 HC

PBMC, peripheral blood mononuclear cells; CSF, cerebrospinal fluid; PD, Parkinson’s disease; HC, healthy controls; TLDA, TaqMan low-density array; qRT-PCR, quantitative Reverse Transcription PCR; NGS, Next Generation Sequencing; ^*first cohort of validation; ^**second cohort of validation; ↑ or ↓ symbolize up- or downregulation of miRNAs expression.